Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP‐treated drug‐naïve primates
Identifieur interne : 002557 ( Main/Curation ); précédent : 002556; suivant : 002558Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP‐treated drug‐naïve primates
Auteurs : Lance A. Smith [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Ghassan Al-Barghouthy [Royaume-Uni] ; Sarah Rose [Royaume-Uni] ; Mikko Kuoppamaki [Royaume-Uni, États-Unis] ; Warren Olanow [Finlande] ; Peter Jenner [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 2005-03.
English descriptors
Abstract
Long‐acting dopamine agonist drugs induce a lower incidence of dyskinesia in MPTP‐treated primates and patients with Parkinson's disease compared to pulsatile treatment with levodopa, supporting the concept of continuous dopaminergic stimulation as a means of dyskinesia avoidance. We examined the effects of L‐dopa administered with or without the COMT inhibitor entacapone on dyskinesia induction in previously untreated MPTP‐treated common marmosets. Administration of L‐dopa (12.5 mg/kg p.o.) plus carbidopa twice daily produced fluctuating improvement in motor behavior coupled with dyskinesia. Coadministration with entacapone produced similar patterns of motor improvement and dyskinesia that were not different from that produced by L‐dopa alone. Treatment with L‐dopa (6.25 mg/kg p.o.) plus carbidopa four times daily reversed motor disability and induced dyskinesia in a manner that was not different from the twice‐daily treatment regimens. However, coadministration with entacapone produced more continuous improvement in locomotor activity with less dyskinesia than animals treated with L‐dopa four times daily alone. These data support the notion that pulsatile stimulation contributes to the development of dyskinesia and suggests that more frequent dosing of L‐dopa plus entacapone may be a useful treatment strategy for patients in the early stages of Parkinson's disease. © 2004 Movement Disorder Society
Url:
DOI: 10.1002/mds.20317
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002907
Links to Exploration step
ISTEX:BD388FE8C220A542359930412AA51EAEE3F12AEFLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP‐treated drug‐naïve primates</title><author><name sortKey="Smith, Lance A" sort="Smith, Lance A" uniqKey="Smith L" first="Lance A." last="Smith">Lance A. Smith</name><affiliation wicri:level="1"><mods:affiliation>Neurodegenerative Diseases Research Centre, GKT School of Biomedical Sciences, King's College, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, GKT School of Biomedical Sciences, King's College, London</wicri:regionArea></affiliation></author><author><name sortKey="Jackson, Michael J" sort="Jackson, Michael J" uniqKey="Jackson M" first="Michael J." last="Jackson">Michael J. Jackson</name><affiliation wicri:level="1"><mods:affiliation>Neurodegenerative Diseases Research Centre, GKT School of Biomedical Sciences, King's College, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, GKT School of Biomedical Sciences, King's College, London</wicri:regionArea></affiliation></author><author><name sortKey="Al Arghouthy, Ghassan" sort="Al Arghouthy, Ghassan" uniqKey="Al Arghouthy G" first="Ghassan" last="Al-Barghouthy">Ghassan Al-Barghouthy</name><affiliation wicri:level="1"><mods:affiliation>Neurodegenerative Diseases Research Centre, GKT School of Biomedical Sciences, King's College, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, GKT School of Biomedical Sciences, King's College, London</wicri:regionArea></affiliation></author><author><name sortKey="Rose, Sarah" sort="Rose, Sarah" uniqKey="Rose S" first="Sarah" last="Rose">Sarah Rose</name><affiliation wicri:level="1"><mods:affiliation>Neurodegenerative Diseases Research Centre, GKT School of Biomedical Sciences, King's College, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, GKT School of Biomedical Sciences, King's College, London</wicri:regionArea></affiliation></author><author><name sortKey="Kuoppamaki, Mikko" sort="Kuoppamaki, Mikko" uniqKey="Kuoppamaki M" first="Mikko" last="Kuoppamaki">Mikko Kuoppamaki</name><affiliation wicri:level="1"><mods:affiliation>Neurodegenerative Diseases Research Centre, GKT School of Biomedical Sciences, King's College, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, GKT School of Biomedical Sciences, King's College, London</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Mount Sinai School of Medicine, New York, New York, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Mount Sinai School of Medicine, New York, New York</wicri:regionArea></affiliation></author><author><name sortKey="Olanow, Warren" sort="Olanow, Warren" uniqKey="Olanow W" first="Warren" last="Olanow">Warren Olanow</name><affiliation wicri:level="1"><mods:affiliation>Satakunta Central Hospital and Satakunnan Neurologipalvelu Oy, Pori, Finland</mods:affiliation><country xml:lang="fr">Finlande</country><wicri:regionArea>Satakunta Central Hospital and Satakunnan Neurologipalvelu Oy, Pori</wicri:regionArea></affiliation></author><author><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name><affiliation wicri:level="1"><mods:affiliation>Neurodegenerative Diseases Research Centre, GKT School of Biomedical Sciences, King's College, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, GKT School of Biomedical Sciences, King's College, London</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:BD388FE8C220A542359930412AA51EAEE3F12AEF</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1002/mds.20317</idno><idno type="url">https://api.istex.fr/document/BD388FE8C220A542359930412AA51EAEE3F12AEF/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002907</idno><idno type="wicri:Area/Main/Curation">002557</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP‐treated drug‐naïve primates</title><author><name sortKey="Smith, Lance A" sort="Smith, Lance A" uniqKey="Smith L" first="Lance A." last="Smith">Lance A. Smith</name><affiliation wicri:level="1"><mods:affiliation>Neurodegenerative Diseases Research Centre, GKT School of Biomedical Sciences, King's College, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, GKT School of Biomedical Sciences, King's College, London</wicri:regionArea></affiliation></author><author><name sortKey="Jackson, Michael J" sort="Jackson, Michael J" uniqKey="Jackson M" first="Michael J." last="Jackson">Michael J. Jackson</name><affiliation wicri:level="1"><mods:affiliation>Neurodegenerative Diseases Research Centre, GKT School of Biomedical Sciences, King's College, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, GKT School of Biomedical Sciences, King's College, London</wicri:regionArea></affiliation></author><author><name sortKey="Al Arghouthy, Ghassan" sort="Al Arghouthy, Ghassan" uniqKey="Al Arghouthy G" first="Ghassan" last="Al-Barghouthy">Ghassan Al-Barghouthy</name><affiliation wicri:level="1"><mods:affiliation>Neurodegenerative Diseases Research Centre, GKT School of Biomedical Sciences, King's College, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, GKT School of Biomedical Sciences, King's College, London</wicri:regionArea></affiliation></author><author><name sortKey="Rose, Sarah" sort="Rose, Sarah" uniqKey="Rose S" first="Sarah" last="Rose">Sarah Rose</name><affiliation wicri:level="1"><mods:affiliation>Neurodegenerative Diseases Research Centre, GKT School of Biomedical Sciences, King's College, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, GKT School of Biomedical Sciences, King's College, London</wicri:regionArea></affiliation></author><author><name sortKey="Kuoppamaki, Mikko" sort="Kuoppamaki, Mikko" uniqKey="Kuoppamaki M" first="Mikko" last="Kuoppamaki">Mikko Kuoppamaki</name><affiliation wicri:level="1"><mods:affiliation>Neurodegenerative Diseases Research Centre, GKT School of Biomedical Sciences, King's College, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, GKT School of Biomedical Sciences, King's College, London</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Mount Sinai School of Medicine, New York, New York, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Mount Sinai School of Medicine, New York, New York</wicri:regionArea></affiliation></author><author><name sortKey="Olanow, Warren" sort="Olanow, Warren" uniqKey="Olanow W" first="Warren" last="Olanow">Warren Olanow</name><affiliation wicri:level="1"><mods:affiliation>Satakunta Central Hospital and Satakunnan Neurologipalvelu Oy, Pori, Finland</mods:affiliation><country xml:lang="fr">Finlande</country><wicri:regionArea>Satakunta Central Hospital and Satakunnan Neurologipalvelu Oy, Pori</wicri:regionArea></affiliation></author><author><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name><affiliation wicri:level="1"><mods:affiliation>Neurodegenerative Diseases Research Centre, GKT School of Biomedical Sciences, King's College, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, GKT School of Biomedical Sciences, King's College, London</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-03">2005-03</date><biblScope unit="volume">20</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="306">306</biblScope><biblScope unit="page" to="314">314</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">BD388FE8C220A542359930412AA51EAEE3F12AEF</idno><idno type="DOI">10.1002/mds.20317</idno><idno type="ArticleID">MDS20317</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>MPTP</term><term>continuous dopaminergic stimulation</term><term>dyskinesia</term><term>entacapone</term><term>levodopa</term><term>primates</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Long‐acting dopamine agonist drugs induce a lower incidence of dyskinesia in MPTP‐treated primates and patients with Parkinson's disease compared to pulsatile treatment with levodopa, supporting the concept of continuous dopaminergic stimulation as a means of dyskinesia avoidance. We examined the effects of L‐dopa administered with or without the COMT inhibitor entacapone on dyskinesia induction in previously untreated MPTP‐treated common marmosets. Administration of L‐dopa (12.5 mg/kg p.o.) plus carbidopa twice daily produced fluctuating improvement in motor behavior coupled with dyskinesia. Coadministration with entacapone produced similar patterns of motor improvement and dyskinesia that were not different from that produced by L‐dopa alone. Treatment with L‐dopa (6.25 mg/kg p.o.) plus carbidopa four times daily reversed motor disability and induced dyskinesia in a manner that was not different from the twice‐daily treatment regimens. However, coadministration with entacapone produced more continuous improvement in locomotor activity with less dyskinesia than animals treated with L‐dopa four times daily alone. These data support the notion that pulsatile stimulation contributes to the development of dyskinesia and suggests that more frequent dosing of L‐dopa plus entacapone may be a useful treatment strategy for patients in the early stages of Parkinson's disease. © 2004 Movement Disorder Society</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002557 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 002557 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Curation
|type= RBID
|clé= ISTEX:BD388FE8C220A542359930412AA51EAEE3F12AEF
|texte= Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP‐treated drug‐naïve primates
}}
| This area was generated with Dilib version V0.6.23. |  |